Clinical Development of Orphan D

Informa Life Sciences Orphan Drugs event aims to create a unique opportunity for patient organisations, pharmaceutical and biotech companies.

Health & Fitness, Medical & Health Care

Clinical Development of Orphan D 24-25 Feb 2015 Park Plaza Victoria London, London, United Kingdom
Submit new post
Thank you for posting.
Share it:

A unique opportunity to build new relationships and improve existing partnerships between industry and patient organisations

Clarifying Regulations for Orphan Drugs with case-studies & recommendations to help you overcome common pitfalls in adhering to drug development regulations

Benchmark your orphan drug development programme against leading players such as Pfizer, GSK, Roche & NPS Pharma

Overcome challenges and gain solutions for small populations, critical considerations for trial design & strategies to boost patient enrollment & retention

Improve partnerships with patient organisations with critical recommendations for effective partnering

Get the most from your joint HTA/EMA meeting with critical insight and first-hand advice from NICE

Understand off-label use and its implications for product approval

Arrange one-to-one meetings with key stakeholders via EBD’s partnering system, groupsPLUS


Price: FLASH RATE: GBP 999

Speakers: Martin Andrews, Senior VP Rare Diseases GSK, Leeza Osipenko, Associate Director NICE Scientific Advice, Michael Skynner, Head of External Alliances, Rare Disease Unit, Pfizer, Friedrich Metzger, Head of Discovery Rare Diseases, F.Hoffman-La Roche Ltd, Nicolas Sireau, Chairman and CEO, AKU Society, Bruce Bloom, President and Chief Scientific Officer, Cures Within Reach

From: February 24, 2015 09:00
To: February 25, 2015 18:00

Park Plaza Victoria London, 239 Vauxhall Bridge Rd, SW1V 1EQ, London, United Kingdom


Health & Fitness, Medical & Health Care


fitness, health, health care

Contact email

Contact phone
+44 0000000000


Submitted by:

evvnt Platform

Are you the organizer?

Get in touch